This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
The health outcomes referred to lung functions, airway hyper-responsiveness and quality of life. The outcomes measured were the forced vital capacity (FVC), FEV1, FEV% (FEV1/FVC), PEF, the provocative dose of histamine needed to cause a 15% drop in FEV1 (PD15), and the health-related quality of life (HRQOL). HRQOL was measured by the generic 15D, and the disease-specific St.George's Respiratory Questionnaire (SGRQ). The relative risk for sickness days during the whole follow-up period was also assessed.
Effectiveness results
Apart from FVC, all outcomes improved significantly in both of the study groups. The changes in the values of the variables were as follows.
FVC: 1.0 (95% confidence interval, CI: -4.1 -1.9) in the IG and -0.3 (95% CI: -3.3 -2.7) in the CG. FEV1: 3.3 (95% CI: 0.2 -6.4, p<0.05) in the IG and 1.8 (95% CI: -1.3 -5.0) in the CG. FEV%: 3.1 (95% CI: 1.1, 5.1, p<0.01) in the IG and 3.0 (95% CI: 1.2 -4.7, p<0.001) in the CG. PEF: 7.2 (95% CI: 4.6 -9.6, p<0.001) in the IG and 4.6 (95% CI: 1.9 -7.4, p<0.01) in the CG. PD15 dose step: 1.4 (95% CI: 1.0 -1.5, p<0.001) in the IG and 1.0 (95% CI: 0.8 -1.4, p<0.001) in the CG. 15D: 0.04 (95% CI: 0.02 -0.05, p<0.001) in the IG and 0.04 (95% CI: 0.02 -0.05, p<0.001) in the CG. SGRQ (total score): 12.0 (95% CI: 8.3 -14.8, p<0.001) in the IG and 14.1 (95% CI: 10.8 -17.0, p<0.001) in the CG.
There was no significant difference between the two groups in terms of the above changes.
There had been a significant difference at one year in FEV1, (p=0.02), and at 3 years in terms of the PD15 (p=0.04).
The authors stated that, compared with the CG, there had been a significantly lower relative risk for sickness days during the whole follow-up period in the IG. The odds ratio was 0.33 (95% CI: 0.28 -0.40). The authors reported two supplementary pieces of information relating to the whole 5-year period, and suggested that these argued in favour of the IG. First, 152 sickness days were lost by the IG patients and 398 days were lost by the CG patients, (p=0.07). Second, 35 patients in the IG group and 23 in the CG group, (p=0.005), made recordings of their PEF, which could be seen as an indication of patient compliance. The patients' health improved in both treatment groups. Five years after the start of the intervention, it could not be shown that there was any significant difference between the improvements in the groups.
Clinical conclusions

Modelling
The costing was carried out prospectively on the same patient sample as that used in the effectiveness analysis.
Measure of benefits used in the economic analysis
The effectiveness analysis showed that there was no significant difference between the two groups of patients, 5 years after the intervention began. Therefore, the economic analysis was based on the differences in costs between the two groups.
Direct costs
The costs were calculated for asthma medication (information only available after year 1), oral corticosteroids and antibiotics (average retail price used), patient education, visits to the outpatient clinic, inpatients days, emergency visits, and the nurse and physiotherapist time (13/hour). The cost of asthma medication was obtained from the Finnish Social Insurance Institution. The costs of patient education, outpatient and emergency visits, and inpatient days were obtained from the South Karelia Central hospital.
Discounting was not carried out in the main analysis. In a sensitivity analysis, 3% and 6% were used as possible values.
The quantities and costs were not analysed separately. Some costs were excluded because they were common to both groups. These were the costs of diagnosis, visit for randomisation, and the follow-up visits at 12 months, 36 months and 5 years. The costs of drop-outs were not included in the analysis, but these were no different from the costs of those who remained in the study.
Statistical analysis of costs
Statistical analysis of the total costs was carried out to test for statistical significance of the results.
Indirect Costs
The patient's time taken to attend clinic and the days off sick were included in the analysis, the details of which were published elsewhere (see Other Publications of Related Interest). The price year was not given. Discounting was carried out in the sensitivity analysis at 3% and 6%.
1,213). The corresponding values in the CG were 1,064 (range of mean: 0 -72,623) and 787 (range of median: 546 -1,244).
Total costs: in the IG, the mean cost was 1,906 (range: 726 -7,506) and the median was 1,727 (range: 1,319 -2,241). The corresponding costs in the CG were 2,286 (range of mean: 636 -9,842) and 1,640 (range of median: 1,283 -2,668).
The differences in the costs between the two groups were not statistically significant.
The duration of the costs was 5 years.
Synthesis of costs and benefits
The costs and benefits were not combined, since there was no statistically significant difference in both costs and effectiveness measures.
Authors' conclusions
There was no long-term difference in terms of the effectiveness between the two groups of patients. The intensive intervention (IG) cost less than the control intervention (CG), but this result was not statistically significant.
CRD COMMENTARY -Selection of comparators
The comparator, a conventional patients education programme for one month, was valid. It had been justified in an earlier paper (see Other Publications of Related Interest) reporting earlier results. The comparator was standard practice in the authors' country, Finland. You should assess whether it represents a currently used intervention in your own setting.
Validity of estimate of measure of effectiveness
The source of the effectiveness data was the authors' study. The study design, a randomised controlled trial, was appropriate for the study question. All of the patients had agreed to participate in the study, thus the patients studied were likely to be representative of the study population. The patient groups were shown to be comparable at baseline. Generally, the analysis of effectiveness was handled credibly. However, the authors did not state whether the measurements of lung function were taken at the same time of day. Also, the authors noted that there had been a significant difference in the number of sick days taken between the two groups, fewer being taken by the IG than the CG. They did not, however, give the time profile of the days taken off, so that it could be seen whether this was likely to continue after the 5-year follow-up.
Validity of estimate of measure of benefit
The authors concluded that there was no statistically significant difference between the effectiveness of the two interventions, and therefore, did not derive a summary measure of health benefit.
Validity of estimate of costs
All the relevant categories of costs were included. However, the first year of the drug costs was not included. Some of the costs common to both interventions were excluded, such as the costs of diagnosis, randomisation visit, and the follow-up visits at 12 months, 36-months and 5 years. The quantities were not reported separately from the prices. Therefore, it could not be seen how sensitive the results were to changes in the drug prices or costs of medical personnel. Also, the authors did not explain clearly how prices had been converted from Finnish marks to UK pounds sterling, that is, whether they used a constant exchange rate or a different one each year. The authors also did not state whether the drug prices had been converted to a constant price year. These issues are important because if the costs were treated correctly, the study might have shown a statistically significant difference between the two kinds of intervention.
